Aurinia Pharmaceuticals Inc Dossier - Source-backed chat

Aurinia Pharmaceuticals Inc

AUPHNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.27

Intrinsic Value $14.50median of 5 methods · middle span $9-$18based on filings through 30 Jun 2026

Market Price $16.20Price as of 30 Sep 2026

Near fair valueIntrinsic value is 11% below the market price

−50% · IV below pricenear fair value ±15%IV above price · +50%

Data confidence Sign in to view data confidence

Market Cap $2.2B

Enterprise Value $2B

Shares Outstanding 134M diluted

Moat Rating Wide

Next Earnings Date9 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Aurinia Pharmaceuticals represents a compelling commercial-stage biotechnology investment under newly consolidated activist leadership. Following a sweeping C-suite overhaul in March 2026, biotech takeover specialist Kevin Tang (President of Tang Capital Management) assumed the CEO role, aligning management incentives directly with shareholders by electing to receive zero salary, bonuses, or equity compensation. The company's core asset, LUPKYNIS (voclosporin), continues to demonstrate robust commercial momentum, delivering 24% year-over-year revenue growth in Q1 2026 to $77.7 million and generating $32.6 million in operating cash flow. Furthermore, the strategic acquisition of Kezar Life Sciences (completed in May 2026) diversifies Aurinia's pipeline beyond a single-product profile by adding zetomipzomib, a promising first-in-class immunoproteasome inhibitor. Backed by a strong balance sheet with $378.8 million in cash and investments as of March 31, 2026, and zero debt, Aurinia is well-positioned to fund its pipeline internally while continuing aggressive share repurchases.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets7 analysts · as of 18 Aug 2026

Low · most bearish analyst$15.00

Mean target$17.00

High · most bullish analyst$20.00

Street targets sit above today's price; our intrinsic value sits below it. Different horizons, different questions.

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 18 Sep 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$15.00

LUPKYNIS sales growth flattens due to intense competition from therapeutic alternatives like Gazyva or Benlysta. Zetomipzomib or aritinercept encounter clinical development delays, safety signals, or regulatory hurdles, leaving the company heavily dependent on a single commercial asset. Increased R&D spending on the expanded pipeline compresses operating margins.

Base CaseCentral scenario

$17.00

Matches the consensus mean

LUPKYNIS net product sales meet the reaffirmed 2026 guidance of $305 million to $315 million, representing steady low-to-mid teens growth. Aritinercept and zetomipzomib progress through early-to-mid stage clinical trials without major safety setbacks. The company maintains positive cash flow and continues to execute its share buyback program, supporting a steady re-rating toward historical valuation multiples.

Bull CaseUpside scenario

$20.00

LUPKYNIS commercial adoption accelerates faster than expected, driven by the updated 2024 ACR LN guidelines recommending triple immunosuppressive therapy. Zetomipzomib delivers outstanding Phase 2b/3 data in autoimmune hepatitis, significantly expanding the addressable market. Operating leverage scales rapidly under Kevin Tang's cost-disciplined management, leading to substantial earnings beats and potential acquisition interest from large pharma.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Direct alignment of interest with activist CEO Kevin Tang, who receives no salary, bonuses, or equity compensation.
Strong commercial execution of LUPKYNIS, delivering high-margin revenue growth (92% gross margin in Q1 2026).
Robust balance sheet with $378.8 million in cash and investments as of March 31, 2026, and zero debt.
Pipeline diversification through the completed acquisition of Kezar Life Sciences, adding the first-in-class asset zetomipzomib.

Key Investment Risks

Single-product commercial dependence on LUPKYNIS for near-term revenue generation.
Potential competitive pressure in the lupus nephritis space from established biologics like Benlysta and upcoming launches like Gazyva.
Clinical development and regulatory risks associated with newly acquired pipeline assets (zetomipzomib) and early-stage candidates (aritinercept).

Thesis Invalidation Triggers

A material deceleration or year-over-year decline in LUPKYNIS net product sales.
Severe clinical safety signals or trial failures for zetomipzomib or aritinercept.
Unexpected regulatory interventions or labeling restrictions imposed on LUPKYNIS.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.